Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development

Oct 29 2018

• By Joseph Haas and Jo Shorthouse

Morrie Birnbaum of Pfizer — Pfizer's Morris Birnbaum

Related Content

Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds

Apr 30 2018

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

Jan 13 2017

In Novartis, Conatus Lands Experienced, Deep-Pocketed NASH Partner

Dec 20 2016

Combination Strategies A Common Thread In NASH R&D

Nov 21 2016

Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?

Apr 19 2017

Related Companies

Intercept Pharmaceuticals, Inc.

Genfit SA

Pfizer Inc.

Novartis AG

Gilead Sciences, Inc.

Enanta Pharmaceuticals, Inc.

Allergan plc

Conatus Pharmaceuticals Inc.

Additional Topics

Deals Research & Development Business Strategies Clinical Trials Liver & Hepatic BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window